


Amendments to the Specification:

Please delete the entire paragraph at lines 20 – 29 of page 3, and replace with the following new paragraph:

According to the present invention, there is provided a metallocene compound **1** for use as a medicament in the treatment of cancer.




In **1**: R¹, R², R³ and R⁴ represent a combination of H, alkyl, aryl or trimethylsilyl;

Please replace the paragraph at lines 21 – 25 of page 4 with the following amended paragraph:

A least one cyclopentadienyl ring is functionalised by means of the group L such that the compound is water soluble. Preferably the at least one cyclopentadienyl ring is functionalised by a group L that carries a ~~pendant~~ pendent Lewis base which confers aqueous solubility, such as an amino-functionalised side chain which can be quaternised.

Please replace the paragraph from lines 27 of page 4 – line 6 of page 5 with the following amended paragraph:


Typically, in order to functionalise the cyclopentadienyl ring, the group L comprises an alkyl group with a terminal Lewis base and preferably L has the formula




wherein n or q is an integer from 1 to 20 and Z comprises an amino group, for instance a secondary amino group, a particularly favoured example being a $-(CH_2)_2N(CH_2)_5$ group, which may be quaternised to provide compounds such as those of formula 2 or 3. These compounds may comprise trialkyl ammonium halides, such as the compound of formula 2 or, most advantageously, novel tetraalkylammonium compounds including the compound of formula 3.


Please delete the entire paragraph from line 6 of page 6 – line 7 of page 7, and replace with the following new paragraph:

Particular examples of compounds wherein only one of the L groups comprises a functionalised substituent include those of formulae 4, 5, 6, and 7.






5



6



7